Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients with Metastatic Pancreatic Cancer

Summary

The purpose of this study is to evaluate the safety and efficacy of LY3214996 in combination with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.

General Information

NCT#: NCT04386057
Study ID: 19-529
Trial Phase: Phase II

Trial Sponsor: Eli Lilly, Kimberly Perez
Therapies Used in This Trial: Hydroxychloroquine, LY3214996

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search